Prostate Cancer CTC PSMA Status Could Guide Therapy
PSMA expression on circulating tumor cells in men with mCRPC increases upon disease progression despite treatment with novel antiandrogens.
All articles by John Schieszer, MA
Study May Help Define Role of PSMA PET/CT in Recurrent Prostate Cancer
Recent findings suggest it may be possible to spare patients unnecessary exposure to radiation.
Persistent PSA After Salvage RP Predicts Worse Outcomes in Prostate Cancer Patients
Persistent PSA after salvage radical prostatectomy is linked to an increased risk of adverse outcomes in patients with prostate cancer.
Dabrafenib Plus Trametinib Could Be New Standard in Pediatric Low-Grade Glioma
Dabrafenib plus trametinib improved the overall response rate and prolonged progression-free survival, compared with standard chemotherapy.
Veliparib With Adjuvant Temozolomide May Benefit Select Patients With Glioblastoma With MGMT Promoter Hypermethylation
A subset of patients treated with temozolomide plus veliparib may have extended survival following retreatment with temozolomide at first recurrence.
ASCT Extends PFS in Newly Diagnosed Multiple Myeloma
Transplant after a 3-drug induction regimen can prolong progression-free survival, compared with triplet induction alone, in patients with multiple myeloma.
IKEMA Update Reveals “Unprecedented” PFS in Relapsed Multiple Myeloma
Adding isatuximab to carfilzomib and dexamethasone significantly improved progression-free survival at a median follow-up of 44 months.
Lack of Access, Not Lack of Interest, Prevents Black Patients From Enrolling in Clinical Trials
More than 80% of Black survey respondents said they were somewhat or very likely to consider enrolling in a clinical trial.
Increasing Public Welfare Spending Can Improve Survival for Black Cancer Patients
A 10% increase in public welfare spending was associated with an 8.6% improvement in 5-year overall survival for Black patients with cancer.
Hispanic Children With High-Risk Neuroblastoma Have Worse Outcomes
Hispanic children had inferior overall survival despite receiving the same treatment as their peers.
- Loading...
Loading...
Loading... 
Loading...